Abstract:
A three-helix bundle protein, a polynucleotide encoding the three-helix bundle protein, a method of preparing the three-helix bundle protein, and a method of treating a cancer using the three-helix bundle protein.
Abstract:
A p16 protein variant; a polynucleotide encoding the p16 protein variant; a method for preparing the p16 protein variant; a pharmaceutical composition comprising the p16 protein variant; a method for preventing and/or treating cancer comprising administering the p16 protein variant to a subject; and use of the p16 protein variant in the prophylaxis and/or therapy of cancer.
Abstract:
A fusion protein including a targeting moiety, a cleavage site, and a cell membrane penetrating domain, a conjugate including the fusion protein and a bioactive molecule, and methods employing the fusion protein and the conjugate are provided.
Abstract:
Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same.
Abstract:
A protein complex comprising a first polypeptide comprising a first antigen-binding region; a second polypeptide comprising a second antigen-binding region; anda linker connecting the first polypeptide and the second polypeptide, wherein the first antigen-binding region is a single stranded polypeptide comprising a first light chain antigen-binding region and a first heavy chain antigen-binding region, the second antigen-binding region is a single stranded polypeptide comprising a second light chain antigen-binding region and a second heavy chain antigen-binding region, and the linker connects the C-terminal of the first polypeptide and the N-terminal of the second polypeptide, and comprises a tag including a cleavable amino acid sequence at one terminal or both terminals of the linker; as well as a bispecific antibody derived from the protein complex, and related compositions and methods.
Abstract:
A three-helix bundle protein, a polynucleotide encoding the three-helix bundle protein, a method of preparing the three-helix bundle protein, and a method of treating a cancer using the three-helix bundle protein.
Abstract:
A p16 protein variant; a polynucleotide encoding the p16 protein variant; a method for preparing the p16 protein variant; a pharmaceutical composition comprising the p16 protein variant; a method for preventing and/or treating cancer comprising administering the p16 protein variant to a subject; and use of the p16 protein variant in the prophylaxis and/or therapy of cancer.
Abstract:
A leucine zipper variant, a polynucleotide encoding the leucine zipper variant, a method of preparing a leucine zipper variant, a method of inhibiting HDM2- and/or HDMX using the leucine zipper variant, and a method of the prevention and/or treatment of cancer using the leucine zipper variant.
Abstract:
Provided is a chemically modified targeting protein, a pharmaceutical composition including the chemically modified targeting protein, a conjugate including the chemically modified targeting protein and a drug, and methods for preparing the same.
Abstract:
In one example embodiment of the inventive concepts, an adaptive data backup method performed in a memory system including a non-volatile multi-level cell memory device includes receiving a write command from a host and determining a backup data size which is a size of data to be backed up among data requested to be written in the write command. The adaptive data backup method further includes selecting a backup type among at least two different backup types, based on the backup data size and backing up the data according to the selected backup type.